Nrf-2-SLC7A11-GSH pathway

The Nrf-2-SLC7A11-GSH pathway is a redox-regulatory cascade in which the transcription factor Nrf2 drives expression of SLC7A11 (xCT), the light chain of the cystine/glutamate antiporter system xc−, which imports cystine in exchange for exporting glutamate and so supplies the cysteine that limits glutathione (GSH) synthesis. Under basal conditions Nrf2 is bound by Kelch-like ECH-associated protein 1 (KEAP1) and continuously degraded; oxidative or electrophilic stress modifies reactive cysteines on KEAP1, releasing Nrf2 to accumulate in the nucleus and induce cytoprotective genes including SLC7A11 and heme oxygenase 1. The resulting GSH sustains glutathione peroxidase 4 (Gpx4), which reduces lipid hydroperoxides and limits reactive oxygen species accumulation. The axis therefore couples antioxidant transcription, cystine transport and thiol metabolism into one defense against oxidative stress — with a cost, since the obligatory glutamate export can increase extracellular glutamate and disrupt glutamate balance in tissues such as brain.

Because Gpx4 depends on GSH, the cascade governs ferroptosis, the iron-dependent death driven by lipid peroxidation and promoted by acyl-CoA synthetase long-chain family member 4 (ACSL4) and by NCOA4-mediated ferritinophagy. Blocking system xc− — with erastin or with sulfasalazine — starves the cell of cysteine and kills it ferroptotically, while activating the axis reinforces resistance.

That duality defines its pharmacology. Nrf2 activators such as omaveloxolone and natural products including wedelolactone, carvacrol and 10-shogaol are studied for protection in sepsis-induced liver injury, doxorubicin cardiotoxicity and neuromuscular disease such as spinal muscular atrophy. In oncology the same axis is a liability: tumors with KEAP1 loss or Nrf2 gain-of-function mutations, common in non-small cell lung cancer, run the pathway constitutively and resist anticancer treatments including cisplatin, oxaliplatin and the HER2-directed antibody trastuzumab. Elevated tumor GSH is exploited in turn as a chemical trigger for redox-responsive prodrugs, nanocarriers and combined photothermal or sonodynamic platforms.